Background
PsA, psoriatic arthritis, axSpA
DISEASE, PSORIATIC ARTHRITIS, AXIAL SPONDYLOARTHRITIS, RHEUMATOID ARTHRITIS
Currently, there are no commonly accepted criteria for identifying axial involvement in psoriatic arthritis (PsA), and prevalence rates range from 5 to 70% depending on the criteria used for diagnosis and disease duration [The efficacy of upadacitinib, an oral Janus kinase (JAK) inhibitor, to treat adults with active PsA or axial spondyloarthritis (axSpA) has been established in phase 3 clinical trials, with a consistent long-term safety profile observed across rheumatoid arthritis, PsA, and axSpA [